Aclaris Therapeutics (ACRS) Interest & Investment Income (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Interest & Investment Income of -$588000.0 for Q1 2026, down 274.48% year-over-year from $337000.0 in Q1 2025, and down 4623.08% quarter-over-quarter from $13000.0 in Q4 2025.
Aclaris Therapeutics (ACRS) Interest & Investment Income (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Interest & Investment Income history runs 13 years deep, the most recent figure standing at -$588000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 274.48% year-over-year to -$588000.0; the TTM figure through Mar 2026 stood at -$412000.0 (up 83.86% YoY), while the FY2025 annual figure was $513000.0, up 152.71% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$588000.0, down from $13000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $2.3 million in Q3 2023, with the low at -$5.6 million in Q4 2024.
- The 5-year median for Interest & Investment Income is $115000.0 (2025), against an average of $155529.4.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 2880.0% in 2022, then soared 1766.19% in 2023.
- Aclaris Therapeutics' Interest & Investment Income stood at $568000.0 in 2022, then soared by 285.39% to $2.2 million in 2023, then sank by 357.97% to -$5.6 million in 2024, then jumped by 100.23% to $13000.0 in 2025, then tumbled by 4623.08% to -$588000.0 in 2026.
- Business Quant data shows ACRS's Interest & Investment Income at -$588000.0 in Q1 2026, $13000.0 in Q4 2025, and $115000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Mar 31, 2026 | -588,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 337,000.00 |
| Dec 31, 2024 | -5.65 Mn |
| Sep 30, 2024 | 890,000.00 |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | -757,000.00 |
| Mar 31, 2023 | 543,000.00 |
| Dec 31, 2022 | 568,000.00 |
| Sep 30, 2022 | -139,000.00 |
| Jun 30, 2022 | -354,000.00 |
| Mar 31, 2022 | -748,000.00 |
| Dec 31, 2021 | -224,000.00 |
| Sep 30, 2021 | 5,000.00 |